1Boushey CJ, Beresirord SA, Omenn GS, et al. Quantitative assessment of plasma homoeysteine as a risk factor for vascular disease. JAMA, 1995,274(13) : 1049-1057.
2Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for theroselerosis. Ann Pharma Cother, 2000,34 ( 1 ):57- 65.
3Lentz SR. Mechanisms of thrombosis in hyper homocysteinemia. Curr Opin Hematol, 1998,5(5) :343-349.
4Libby P, Ridker PU. Novel inflammatory markers of coronary risk theory versus practiceI (Editorial: comment). Circulation, 1999,100(3) : 1148-1150.
5Ansell BJ,Watson KE, Weiss RE, et al. Hs-CRP and ttDL aeffect Statins Trial(CHEST) :rapid effect of statin therapy on creactive protein an high-density lipoprotein levels:a clinical investigation. Heart Dis,2003,5(1) :2-7.
6Luiji M,Biasucci H,Liuzzo G,et al. Elevated levels of C--reactive protein at discharge in patients with unstable angina predict recurrent insta- bitit y. Circulation, 1999,99 (5) : 855-923.
